Page last updated: 2024-10-20

pteridines and Melanoma

pteridines has been researched along with Melanoma in 12 studies

Melanoma: A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)

Research Excerpts

ExcerptRelevanceReference
"In two groups of patients with checked diagnoses of the malignant melanoma and Hodgkin's disease we followed changes of the renal excretion of two major pterines, neopterine and biopterine."7.67Renal excretion of neopterine and biopterine in patients with malignant melanoma and Hodgkin's disease. ( Andrysek, O; Cernovská, I; Vasícková, M; Zitko, M, 1986)
"BI 2536 is a selective and potent small-molecule inhibitor of polo-like kinase 1."6.75Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research ( Aerts, C; Allgeier, A; Blay, JY; Bogaerts, J; Brain, E; De Greve, J; Fontaine, C; Fritsch, H; Hanft, G; Lacombe, D; Machiels, JP; Munzert, G; Rapion, J; Ray-Coquard, I; Schöffski, P; Sleijfer, S; Soria, JC; Wolter, P, 2010)
"Melanoma is one of the most treatment-resistant malignancies and regardless of new therapeutic tactics the outcome remains dismal."5.38In vitro PLK1 inhibition by BI 2536 decreases proliferation and induces cell-cycle arrest in melanoma cells. ( Brassesco, MS; de Oliveira, JC; Montaldi, AP; Morales, AG; Pezuk, JA; Sakamoto-Hojo, ET; Scrideli, CA; Tone, LG; Valera, ET, 2012)
" We used an exploratory study into plasma concentrations of large neutral amino acids, 5-hydroxyindolacetic acid (5-HIAA), total biopterin (BIOP) and neopterin (NEOP) in 40 high-risk melanoma patients."5.11Pegylated interferon-alpha2b treatment in melanoma patients: influence on amino acids, 5-hydroxyindolacetic acid and pteridine plasma concentrations. ( Bannink, M; Eggermont, AM; Fekkes, D; Kruit, WH; Mulder, PG; Stoter, G; Van Gool, AR; van Ojik, HH, 2004)
"The effect was studied of a number of synthetic indoleamines, pteridines, beta-carbolines, of AVT and of crude extracts from rat and ovine pineal glands on human melanoma cells in vitro."3.67Growth-inhibiting effect of crude pineal extracts on human melanoma cells in vitro is different from that of known synthetic pineal substances. ( Bartsch, C; Bartsch, H; Ebels, I; Flehmig, B; Noteborn, HP; Salemink, CA, 1987)
"In two groups of patients with checked diagnoses of the malignant melanoma and Hodgkin's disease we followed changes of the renal excretion of two major pterines, neopterine and biopterine."3.67Renal excretion of neopterine and biopterine in patients with malignant melanoma and Hodgkin's disease. ( Andrysek, O; Cernovská, I; Vasícková, M; Zitko, M, 1986)
"BI 2536 is a selective and potent small-molecule inhibitor of polo-like kinase 1."2.75Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research ( Aerts, C; Allgeier, A; Blay, JY; Bogaerts, J; Brain, E; De Greve, J; Fontaine, C; Fritsch, H; Hanft, G; Lacombe, D; Machiels, JP; Munzert, G; Rapion, J; Ray-Coquard, I; Schöffski, P; Sleijfer, S; Soria, JC; Wolter, P, 2010)
"Melanoma is one of the most treatment-resistant malignancies and regardless of new therapeutic tactics the outcome remains dismal."1.38In vitro PLK1 inhibition by BI 2536 decreases proliferation and induces cell-cycle arrest in melanoma cells. ( Brassesco, MS; de Oliveira, JC; Montaldi, AP; Morales, AG; Pezuk, JA; Sakamoto-Hojo, ET; Scrideli, CA; Tone, LG; Valera, ET, 2012)

Research

Studies (12)

TimeframeStudies, this research(%)All Research%
pre-19903 (25.00)18.7374
1990's1 (8.33)18.2507
2000's1 (8.33)29.6817
2010's7 (58.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Theodosakis, N1
Micevic, G1
Langdon, CG1
Ventura, A1
Means, R1
Stern, DF1
Bosenberg, MW1
Cholewa, BD2
Pellitteri-Hahn, MC1
Scarlett, CO1
Ahmad, N2
Ndiaye, MA1
Huang, W1
Liu, X1
Schöffski, P1
Blay, JY1
De Greve, J1
Brain, E1
Machiels, JP1
Soria, JC1
Sleijfer, S1
Wolter, P1
Ray-Coquard, I1
Fontaine, C1
Munzert, G1
Fritsch, H1
Hanft, G1
Aerts, C1
Rapion, J1
Allgeier, A1
Bogaerts, J1
Lacombe, D1
Mohammad, KS1
Javelaud, D1
Fournier, PG1
Niewolna, M1
McKenna, CR1
Peng, XH1
Duong, V1
Dunn, LK1
Mauviel, A1
Guise, TA1
de Oliveira, JC1
Brassesco, MS1
Pezuk, JA1
Morales, AG1
Valera, ET1
Montaldi, AP1
Sakamoto-Hojo, ET1
Scrideli, CA1
Tone, LG1
Kapoor, S1
Van Gool, AR1
van Ojik, HH1
Kruit, WH1
Bannink, M1
Mulder, PG1
Eggermont, AM1
Stoter, G1
Fekkes, D1
Gregory, CR1
Harmon, BG1
Latimer, KS1
Hafner, S1
Campagnoli, RP1
McManamon, RM1
Steffens, WL1
Bartsch, H1
Bartsch, C1
Noteborn, HP1
Flehmig, B1
Ebels, I1
Salemink, CA1
Zitko, M1
Andrysek, O1
Cernovská, I1
Vasícková, M1
Pomerantz, SH1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Multicenter Parallel Phase II Trial of BI 2536 Administered as One Hour IV Infusion Every 3 Weeks in Defined Cohorts of Patients With Various Solid Tumors. A New Drug Screening Program of the EORTC Network of Core Institutions (NOCI)[NCT00526149]Phase 276 participants (Actual)Interventional2007-07-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trials

2 trials available for pteridines and Melanoma

ArticleYear
Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research
    European journal of cancer (Oxford, England : 1990), 2010, Volume: 46, Issue:12

    Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Feasibility Studies; Female; Head and Neck Neo

2010
Pegylated interferon-alpha2b treatment in melanoma patients: influence on amino acids, 5-hydroxyindolacetic acid and pteridine plasma concentrations.
    Anti-cancer drugs, 2004, Volume: 15, Issue:6

    Topics: Adult; Aged; Amino Acids; Biopterins; Drug Administration Schedule; Female; Humans; Hydroxyindoleace

2004

Other Studies

10 other studies available for pteridines and Melanoma

ArticleYear
p90RSK Blockade Inhibits Dual BRAF and MEK Inhibitor-Resistant Melanoma by Targeting Protein Synthesis.
    The Journal of investigative dermatology, 2017, Volume: 137, Issue:10

    Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Humans; MAP Kinase Kinas

2017
Large-scale label-free comparative proteomics analysis of polo-like kinase 1 inhibition via the small-molecule inhibitor BI 6727 (Volasertib) in BRAF(V600E) mutant melanoma cells.
    Journal of proteome research, 2014, Nov-07, Volume: 13, Issue:11

    Topics: Cell Cycle Proteins; Cell Line, Tumor; Heterogeneous-Nuclear Ribonucleoprotein Group C; Humans; Mela

2014
Small molecule inhibition of polo-like kinase 1 by volasertib (BI 6727) causes significant melanoma growth delay and regression in vivo.
    Cancer letters, 2017, 01-28, Volume: 385

    Topics: Animals; Antineoplastic Agents; Apoptosis; Caspase 3; Cell Cycle Proteins; Cell Line, Tumor; Cell Pr

2017
TGF-beta-RI kinase inhibitor SD-208 reduces the development and progression of melanoma bone metastases.
    Cancer research, 2011, Jan-01, Volume: 71, Issue:1

    Topics: Animals; Base Sequence; Bone Neoplasms; Cell Line, Tumor; Disease Models, Animal; Disease Progressio

2011
In vitro PLK1 inhibition by BI 2536 decreases proliferation and induces cell-cycle arrest in melanoma cells.
    Journal of drugs in dermatology : JDD, 2012, Volume: 11, Issue:5

    Topics: Antineoplastic Agents; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Disease Progressio

2012
New inhibitors of Polo-like kinase 1 function and their emerging role in attenuating tumor growth in systemic malignancies.
    Journal of drugs in dermatology : JDD, 2012, Volume: 11, Issue:12

    Topics: Cell Cycle Proteins; Humans; Melanoma; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pt

2012
Malignant chromatophoroma in a canebrake rattlesnake (Crotalus horridus atricaudatus).
    Journal of zoo and wildlife medicine : official publication of the American Association of Zoo Veterinarians, 1997, Volume: 28, Issue:2

    Topics: Animals; Chromatography, Paper; Chromatophores; Crotalus; Female; Histocytochemistry; Immunohistoche

1997
Growth-inhibiting effect of crude pineal extracts on human melanoma cells in vitro is different from that of known synthetic pineal substances.
    Journal of neural transmission, 1987, Volume: 69, Issue:3-4

    Topics: Animals; Brain; Carbolines; Cell Count; Cell Division; Cell Line; Growth Inhibitors; Humans; Indoles

1987
Renal excretion of neopterine and biopterine in patients with malignant melanoma and Hodgkin's disease.
    Neoplasma, 1986, Volume: 33, Issue:3

    Topics: Biopterins; Chromatography, Thin Layer; Female; Hodgkin Disease; Humans; Kidney; Male; Melanoma; Neo

1986
Tyrosine hydroxylation catalyzed by mammalian tyrosinase: an improved method of assay.
    Biochemical and biophysical research communications, 1964, Jun-01, Volume: 16, Issue:2

    Topics: Animals; Cricetinae; Dihydroxyphenylalanine; In Vitro Techniques; Kinetics; Melanoma; Neoplasms, Exp

1964